Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 4/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | QPCT | Q16769 | 3/20 | 0.37 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.37 |
| ▸ | IDE | P14735 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5772669 | 0.92 | NOS1 (0.42) | HDAC4HDAC6QPCTTBXAS1 | |
| SCHEMBL5773577 | 0.82 | NAMPT (0.35) | NAMPTHDAC4 | |
| SCHEMBL5773350 | 0.81 | TSHR (0.40) | — | |
| SCHEMBL5774298 | 0.81 | TSHR (0.42) | ALOX15 | |
| SCHEMBL5777440 | 0.81 | HDAC8 (0.35) | HDAC4 | |
| SCHEMBL5773778 | 0.80 | PLA2G7 (0.36) | HDAC4HDAC6 | |
| SCHEMBL5771831 | 0.80 | HDAC8 (0.34) | NAMPT | |
| SCHEMBL5775676 | 0.80 | PLA2G7 (0.37) | HDAC4HDAC6 | |
| SCHEMBL5771361 | 0.80 | NAMPT (0.42) | NAMPTTBXAS1 | |
| Trifluoroacetic Acid SCHEMBL5773631 | 0.79 | POLB (0.48) | POLBNAMPTHDAC4HDAC6QPCT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | MOMOSE YU | 2006-04-20 | — | — | US | disclosed |
| US-7022725-B2 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-04 | — | — | US | disclosed |
| US-20040048908-A1 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1340749-A1 | ISOXAZOLE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | INSR, GPR119, INSRR | CYP19A1 117/4885POLB 3996/4885NAMPT 2451/4885 |
| US-20040048908-A1 | Isoxazole derivatives | GPR119, INSR, IRS1 | CYP19A1 62/4885POLB 3909/4885NAMPT 2378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.